Novel strategy targets chronic liver diseases

/in /by

A resesarch team headed by HepaRegeneriX Board Member Lars Zender has presented a new approach to treat hepatocellular carcinoma (HCC) by disturbing the lipid metabolism of tumour cells. 

Read more

Cellectis and Cytovia in US$760m licence deal

/in /by

Cell therapy specialist Cytovia Therapeutics Inc and genome editing expert Cellectis SAS partner to develop iPSC-derived natural killer (NK) cell-based cancer therapies.
 

Read more

Cellink AB acquires Ginolis Oy for €70m

/in /by

Cellink AB will take over all shares of Ginolis Oy, a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries.

Read more

Rentschler Biopharma launches gene therapy subsidiary

/in /by

CDMO Rentschler Biopharma will establish a Center of Excellence for cell and gene therapy through a  new UK subsidiary Rentschler ATMP Ltd.

Read more

German Health Ministry to invest €6.2bn in vaccines

/in /by

The German Health Ministry has requested €6.2bn from the Federal Ministry of Finance to purchase up to 635 million additional doses of COVID-19 vaccines.

Read more

V-Bio Ventures launches second fund at €78m

/in /by

V-Bio Ventures has announced the first closing of its V-Bio Fund 2 at €78m. The fund is focussed on investments into early stage life sciences companies in Belgium and the EU.
 
·      

Read more

Abingworth raises US-$465m for new life sciences fund

/in /by

The transatlantic Abingworth Bioventures 8 Fund has been closed at $464m to invest in US, UK and European life science companies.   

Read more

Two companies aim for 2nd-gen COVID vaccines

/in /by

As rapidly spreading mutants of SARS-CoV-2 are emerging, two Tuebingen-based vaccine developers will develop multivalent COVID-19 vaccines.

Read more